KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Other Accumulated Expenses (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Other Accumulated Expenses for 17 consecutive years, with $5.8 billion as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses rose 13.01% to $5.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.8 billion through Dec 2025, up 13.01% year-over-year, with the annual reading at $5.8 billion for FY2025, 13.01% up from the prior year.
  • Other Accumulated Expenses hit $5.8 billion in Q4 2025 for Abbott Laboratories, down from $5.9 billion in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $5.9 billion in Q3 2025 to a low of $5.1 billion in Q2 2024.
  • Historically, Other Accumulated Expenses has averaged $5.5 billion across 5 years, with a median of $5.4 billion in 2022.
  • Biggest five-year swings in Other Accumulated Expenses: grew 27.29% in 2021 and later decreased 9.34% in 2024.
  • Year by year, Other Accumulated Expenses stood at $5.2 billion in 2021, then increased by 12.82% to $5.8 billion in 2022, then decreased by 7.24% to $5.4 billion in 2023, then dropped by 5.15% to $5.1 billion in 2024, then rose by 13.01% to $5.8 billion in 2025.
  • Business Quant data shows Other Accumulated Expenses for ABT at $5.8 billion in Q4 2025, $5.9 billion in Q3 2025, and $5.7 billion in Q2 2025.